Nerve growth factor (NGF) and its receptors TrkA and p75 play a key role in the development and function of peripheral nociceptive neurons. Here we describe novel technology to selectively photoablate TrkA positive nociceptors through delivery of a phototoxic agent coupled to an engineered NGF ligand and subsequent near infrared (NIR) illumination. We demonstrate that this approach allows for on demand and localized reversal of pain behaviors in mouse models of acute, inflammatory, neuropathic and joint pain. To target peripheral nociceptors we generated a SNAP-tagged NGF derivative, NGF R121W that binds to TrkA/p75 receptors but does not provoke signaling in TrkA positive cells or elicit pain behaviors in mice. NGF R121W-SNAP was coupled to the photosensitizer IRDye®700DX phthalocyanine (IR700) and injected subcutaneously. Following NIR illumination of the injected area, behavioral responses to nociceptive mechanical and sustained thermal stimuli, but not innocuous stimuli, were substantially reduced. Similarly, in models of inflammatory, osteoarthritic and neuropathic pain, mechanical hypersensitivity was abolished for three weeks following a single treatment regime. We demonstrate that this loss of pain behavior coincides with the retraction of neurons from the skin which then re-innervate the epidermis after 3 weeks corresponding with the return of mechanical hypersensitivity. Thus NGF R121W-SNAP -mediated photoablation is a minimally invasive approach to reversibly silence nociceptor input from the periphery, and control pain and hypersensitivity to mechanical stimuli.
Introduction
Current therapeutic strategies for the management of chronic pain such as nonsteroidal antiinflammatory drugs (NSAIDs), antidepressants, and opioids [6; 9; 49] have limited efficacy and may be associated with dependence, tolerance, and serious side effects [29; 59] . To avoid these issues, and develop pain therapies which are more efficacious, much effort has been made in developing strategies to target the peripheral nervous system, and in particular molecules which are selectively expressed in nociceptors. Amongst the most promising of these molecules, nerve growth factor (NGF) and its cognate receptors TrkA/p75 have emerged as frontrunners for the design of next generation analgesics [13; 15; 41-43; 53] .
There is a wealth of data supporting the role of NGF and its receptors in pain signaling. NGF and TrkA are required for the development of the peripheral nervous system; in their absence, both in animal models, and human genetic disease, nociceptive neurons fail to develop, and animals and human patients display severe deficits in pain sensitivity [11; 21; 27; 28; 32; 50; 56] . In the adult peripheral nervous system, TrkA receptors are expressed predominantly on peptidergic nociceptors, and NGF signaling plays an important role in setting pain sensitivity.
Thus cutaneous administration of NGF leads to hyperalgesia within 1-3 hours, both in rodents and humans [20; 33; 34; 47; 52] and endogenous NGF levels are elevated in chronic pain conditions and promote peripheral and central sensitization [36; 40; 48] . The recognition that NGF has a critical role in the generation and potentiation of pain has created a strong rationale for developing methods that interfere with its signaling. The most successful of these approaches has been the development of antibodies against NGF [13] such as tanezumab and fasinumab, which have advanced to phase III trials for osteoarthritis (OA) of knee and hip. There are however a number of safety issues associated with antagonizing NGF, the most prominent of which is a rapidly progressive OA, leading to joint replacement in some trial patients [24] .
Rather than inhibiting NGF signaling at the molecular level, here we have asked whether the NGF ligand may offer a means of accessing nociceptive neurons via their TrkA receptors to deliver a phototoxic agent to silence their activity. To test this hypothesis, we generated a self labelling recombinant NGF-SNAP tag fusion protein that could be covalently conjugated to the NIR photosensitizer IRDye®700DX phthalocyanine (IR700). While injection of NGF SNAP -IR700 and subsequent NIR illumination reduced nociceptive behavior in mice, results were confounded by the fact that NGF is in itself proalgesic. We thus turned to "painless" mutated derivatives of NGF which still bind to receptors but provoke abrogated signaling, in order to deliver the photosensitizer. Such NGF mutants have been described in patients with Hereditary Sensory and Autonomic Neuropathy type 5 (HSAN V), who display a loss of pain perception and other sensory and autonomic abnormalities [1] as a result of mutations in the NGF gene. To date, three mutations in NGF have been identified in HSAN V patients, p.R221W, p.V232fs and p.R121W, that reduce the processing of NGF, alter the neurotrophic activity or abolish the formation of mature NGF-β, respectively [12; 21; 30; 54; 57] . Of these, we selected the NGF p.R121W mutation as a delivery tool as this gave the highest yields in recombinant production when fused to the SNAP tag. We found that NGF R121W-SNAP was able to bind to TrkA positive cells but did not provoke TrkA mediated signaling, or elicit sensitization when injected in mice. Moreover, conjugation of NGF R121W-SNAP to IR700, injection in mice, and subsequent NIR illumination of the injected area led to long term reversal of nociceptive behavior that paralleled retraction of cutaneous nerve fibers from the epidermis. Thus, through ligand guided delivery of a small molecule photosensitizer we are able to achieve selective disruption of nociceptor input, and substantially reduced pain.
Results
Generation and characterization of NGF SNAP .
Recombinant NGF was cloned and purified as a SNAP tag fusion protein (NGF SNAP ), which allows for covalent coupling to BG-derived photosensitizers and imaging fluorophores. We first tested the binding selectivity of NGF SNAP by labelling it with a BG-fluorophore and applying it to cells expressing neurotrophin receptors. NGF SNAP was coupled in vitro to BG-Surface549, and applied at a 100 nM concentration to Hek293T cells transiently transfected with TrkA, TrkB or TrkC and p75. NGF SNAP bound its cognate receptor, decorating the surface of TrkA/p75 transfected cells ( Fig. 1 a) , while cells transfected with BDNF/NT4 and NT3 receptors with p75 were not stained ( Figs. 1 b, c) , demonstrating that binding occurs faithfully in a receptor-specific fashion.
Having confirmed that NGF SNAP specifically labels TrkA expressing cells, we next asked whether a photosensitizer can be coupled to the ligand to ablate TrkA positive cells. Hek293T cells transfected with TrkA/p75 were incubated with NGF SNAP conjugated to the near infrared photosensitizer BG-IR700 and illuminated with NIR light for 2 minutes. 24 hours later cell death was analyzed using propidium iodide staining. In cells transfected with TrkA/p75 we observed concentration dependent increase in cell death upon treatment with NGF SNAP IR700 and NIR illumination ( Figs. 1 d-f ). In the absence of TrkA expression, cell viability was fully preserved following NGF SNAP IR700 application and illumination ( Fig. 1 g) .
We next asked whether NGF SNAP IR700 can be used to photoablate nociceptors in vivo. NGF SNAP conjugated with BG-IR700, ( Fig. 1 h, filled circles) or unconjugated NGF SNAP (open circles) was injected into the hind paw of C57BL/6J male naïve mice, and skin was illuminated for 2 minutes with IR light exposure on 3 consecutive days. Behavioral responses to calibrated Von Frey filaments were monitored after each ablation at 24 hours and 5 days after the last treatment. As shown in figure 1h, mechanical thresholds increased in ablated mice, suggesting that TrkA expressing nociceptors were targeted by NGF SNAP -IR700.
However, we also observed a decrease in von Frey thresholds in control NGF SNAP mice ( Fig.   1h ), indicating that the ligand in itself was having a proalgesic effect and might constitute a confounding factor in the measurement of mechanical thresholds in ablated mice. In further experiments, we thus sought to exploit a "painless" NGF mutant described in HSANV patients, NGF R121W , which has been described to bind to TrkA receptors but not provoke nociceptive signaling [54] .
Generation and characterization of NGF R121W-SNAP
A C-terminal fusion of NGF R121W and SNAP (NGF R121W-SNAP ) was produced in CHO cells at yields similar to wildtype NGF SNAP and could be readily labelled with BG-549 indicating that the SNAP tag was fully functional (Fig. 2 a) . To characterize the binding and signaling properties of NGF R121W-SNAP , we first assessed its capacity to label Hek293T cells transfected with neurotrophin receptor plasmids. NGF R121W-SNAP was coupled in vitro with BG-Surface549 and applied to cells. Similar to wildtype NGF SNAP , we observed robust membrane labelling of TrkA/p75 expressing cells (Fig. 2 b) but no signal in TrkB/p75 or TrkC/p75 transfected cells (Fig 2 c, d) . We further analyzed downstream signaling provoked by wildtype NGF SNAP and NGF R121W-SNAP by assessing phosphorylation of MAPK and AKT upon treatment of PC12 cells with ligands [22] . Wildtype NGF treatment produced a substantial increase in phosphorylation of MAPK and AKT, while levels of MAPK and AKT phosphorylation in cells treated with NGF R121W-SNAP were no different from untreated cells (Fig 2 e, f) . We next evaluated the neurotrophic activity of wildtype NGF and NGF R121W-SNAP by quantifying the number of differentiated PC12 cells (assessed by neurite outgrowth [10] ) after 6 days of incubation with ligands. A significantly higher proportion of differentiated PC12 cells were present in samples treated with NGF SNAP , while those treated with NGF R121W-SNAP were not significantly different from untreated cells ( Fig. 2 g-j) . Finally, we considered the pro-nociceptive activity of NGF SNAP and NGF R121W-SNAP by injecting ligands into the hindpaw of mice and evaluating mechanical and thermal hyperalgesia with the von Frey and hotplate tests. We found that wildtype NGF induced substantial sensitization to both mechanical and thermal stimuli, while injection of NGF R121W-SNAP did not change thresholds to either of these stimuli ( Fig. 2 k, l) . We conclude that, while binding and receptor specificity of NGF R121W-SNAP are comparable to that of NGF SNAP , it has the distinctive advantage that it allows for uncoupling of receptor engagement from nociceptive activity, making it a valuable tool to selectively target TrkA expressing peptidergic neurons for the development of an antinociceptive treatment strategy.
NGF R121W-SNAP -mediated photoablation and acute nociception.
We first assessed the efficacy of NGF R121W-SNAP IR700 mediated photoablation in vitro in Hek293T cells transfected with TrkA/p75. Similar to NGF SNAP , the mutant ligand induced a robust and concentration dependent increase in cell death 24 hours after application to cells and NIR illumination ( Fig. 3 a-c) . In contrast, NGF R121W-SNAP IR700 and NIR illumination was without effect in mock transfected cells not expressing TrkA/p75 ( Fig. 3 d) .
To characterize NGF R121W-SNAP mediated photoablation in vivo, we evaluated its efficacy in models of acute nociception. Wild type C57BL/6J male mice were injected for 3 consecutive days in the hind paw with either NGF R121W-SNAP , with or without IR700, or with IR700 alone (some controls shown in Supplementary Fig. 2 ) followed by NIR illumination. We first tested mice for sensitivity to punctate mechanical stimuli using von Frey filaments. As shown in Fig. 3 e, two days following ablation, mice treated with NGF R121W-SNAP IR700 displayed significantly reduced sensitivity to these stimuli, requiring weights above 3g to provoke a behavioral response, and this insensitivity persisted throughout the 8 day monitoring period.
Similarly, responses to nociceptive pin-prick stimuli applied to the paw were also substantially reduced in photoablated compared to control mice ( Fig. 3 f) . We further assessed sensitivity to non-nociceptive dynamic brush stimuli, and observed no effect of NGF R121W-SNAP IR700 ( Fig. 3 g) indicating that the photoablation is selective for nociceptors.
We also tested thermal responsiveness using the hotplate test. Intriguingly, first line reflex latencies were not different between photoablated and control animals, however, licking behavior evoked by sustained noxious thermal stimuli was reduced in treated animals at 46ºC and 50ºC ( Fig. 3 h, i) . Thus, TrkA positive neurons may mediate pain resulting from tissue damaging thermal stimuli, rather than reflexive defensive responses. Finally, we asked whether NGF R121W-SNAP IR700 can be applied topically to alleviate acute nociception. A micro-emulsion pre-mixed with either NGF R121W-SNAP with or without IR700, or IR700 alone ( Supplementary Fig. 2 e) , was applied to the tail skin and illuminated with NIR light. One week later a calibrated clip was applied to the base of the tail and responses monitored. We observed significantly reduced behavioral responses to the clip in NGF R121W-SNAP IR700 mice throughout the monitoring period, such that mice appeared essentially insensitive to this nociceptive stimulus ( Fig. 3 j, Supplementary Video 1) .
NGF R121W-SNAP -mediated photoablation in models of inflammatory, osteoarthritic and neuropathic pain.
We investigated the effects of NGF R121W-SNAP mediated photoablation on persistent pain using models of inflammatory, osteoarthritic and neuropathic pain.
To model inflammatory pain, mice were injected in the hind paw with complete Freund's adjuvant (CFA). After 48 hours, mechanical and thermal hyperalgesia were evident and mice were treated for three days with NGF R121W-SNAP with or without IR700 ( Supplementary Fig.   2 e), or with NGF R121W-SNAP IR700, with or without near NIR illumination ( Fig. 4 a, b) .
Behavioral thresholds to mechanical and thermal stimuli were monitored for 12 days after CFA injection. As shown in Fig. 4 a, mice which received NGF R121W-SNAP and NIR inflammation displayed a complete reversal of mechanical hypersensitivity that lasted throughout the 12 day observation period ( Fig. 4 a) . Of note, thermal hyperalgesia induced by CFA was not altered by photoablation ( Fig. 4 b) .
To model OA-like pain, mice received an intra-articular injection into the knee of monosodium iodoacetate (MIA) [45] . Seven days post injection, significant fibrosis was evident in the joint (Supplementary Fig. 1 a-f) , and mice developed referred mechanical hypersensitivity to von Frey filaments applied to the plantar surface of the paw ( Supplementary Fig. 1 g) . NGF R121W-SNAP IR700 was injected into the knee and the area was illuminated with NIR light through the skin for 3 consecutive days. Control mice received NGF R121W-SNAP IR700 but no illumination, or IR700 alone with illumination ( Supplementary   Fig. 2 f) . In treated mice, we observed a complete recovery of mechanical thresholds to preinjury levels, which persisted for 3 weeks before returning to the pre-ablation state ( Fig. 4 c) .
Control animals displayed no recovery and remained mechanically hypersensitive throughout the 40 day monitoring period ( Fig. 4 c, Supplementary Fig. 2 
f).
For neuropathic pain, we used the spared nerve injury (SNI) model [17] . 7 days following nerve injury when all mice had developed mechanical hypersensitivity, NGF R121W-SNAP IR700 was injected into the paw and the skin was illuminated with NIR light on 3 consecutive days.
Control animals received NGF R121W-SNAP IR700 without illumination ( Fig. 4 d-f ), IR700 with illumination, or NIR illumination alone ( Supplementary Fig. 2 g) . Mice were then assayed for hypersensitivity to mechanical punctate stimuli, dynamic brush stimuli, and evaporative cooling. In mice treated with NGF R121W-SNAP IR700 and NIR illumination we again observed that thresholds to punctate mechanical stimuli recovered to pre-injury levels for about 3 weeks, before returning to a hypersensitive state ( Fig. 4 d) . Intriguingly, responses to dynamic brushing mechanical stimuli were not altered by photoablation ( Fig. 4 e) , nor were responses to evaporative cooling ( Fig. 4 f) .
Mechanism of NGF R121W-SNAP -mediated photoablation.
To understand how NGF R121W-SNAP mediated photoablation underlies the loss and then recovery of mechanical sensitivity to nociceptive stimuli in treated mice, we performed a histological analysis of skin at 7 and 28 days post treatment.
We first investigated the degree of cell death of non-neuronal cells in the skin by performing TUNEL staining to detect apoptotic DNA fragmentation. Skin was harvested at 7 and 28 days post treatment in animals injected with NGF R121W-SNAP IR700 and illuminated with NIR light, or at 7 days post treatment in control animals receiving only IR700 and illumination. Sections were then processed for TUNEL staining and immunohistochemistry with an anti-K14 antibody to mark keratinocytes. As shown in Figures 5 a-c, very few apoptotic cells could be detected in the skin in all conditions and there was no difference in treated versus control samples ( Fig. 5 a-d) . The number of keratinocytes was also constant across conditions and time points. Thus, at the concentrations and light intensities used here, there is no detectable effect of photoablation on non-neuronal cells in the skin.
To investigate the effects of NGF R121W-SNAP mediated photoablation on innervation of the skin we performed immunohistochemistry using an anti-Pgp9.5 antibody to detect neuronal fibers.
Again, skin samples were taken at 7 and 28 days post treatment in treated animals (NGF R121W-SNAP IR700 plus illumination), or at 7 days post treatment in control animals (IR700 and illumination). We observed a significant reduction in the number of the intra-epidermal free nerve endings in treated animals compared to control at 7 days after injection (Figs. 5 e, f, h).
Importantly, at 28 days post ablation, the number of fibers was restored to a value similar to the one in the control group ( Figs. 5 g, h) . Thus following photoablation, we observe a retraction of nociceptors from the skin that then reinnervate the epidermis with a similar time course to the loss and return of mechanical sensitivity seen in behavioral experiments.
Methods

Animals
Wild type C57BL/6J and Balb/c mice were used at age of 8-10 weeks for all the experiments.
All mice were bred and maintained at the EMBL Neurobiology and Epigenetic Unit, Rome, in accordance with Italian legislation (Art. 9, 27. Jan 1992, no 116). Experiments were performed under license from the Italian Ministry of Health, and in compliance with the ARRIVE guidelines.
Production of recombinant NGF SNAP and NGF R121W-SNAP
cDNAs encoding for murine NGF SNAP and NGF R121W-SNAP including a C-terminal polyhistidine tag (His6) inserted for purification purposes were cloned into the pMB-PB vector as a fusion protein [37] . Protein expression was carried out using Chinese hamster ovary (CHO) cells (ATCC, mycoplasma negative) as described by Balasubramanian [2] . Secreted NGF SNAP and NGF R121W-SNAP were purified from cell medium using a Ni-NTA resin (Qiagen, #30210) and eluted with an excess of imidazole. Eluted fractions were then pooled, concentrated, and stored for further analysis.
Synthesis of BG-IR700
3mg of IRDye®700DX N-hydroxysuccinimide ester fluorophore (LI-COR Biosciences GmbH, Bad Homburg, Germany) were dissolved in 150µl DMSO and treated with 1.5mg BG-PEG 11 -NH 2 and 5µl diisopropylethylamine. After 1h, the product BG-PEG 11 To assess NGF signaling, PC12 cells were cultured on collagen IV-coated 6-well plate in DMEM / F12 medium containing 1% horse serum. Cells were treated for 2 minutes with PBS or 1 µM NGF or 1 µM NGF R121W-SNAP , followed by lysis in Ripa buffer.
In-vitro experiments
For the neuronal differentiation assay, PC12 cells were daily exposed to 100 ng/ml NGF (Alomone labs, #N-100) or NGF R121W-SNAP for 6 days. The number of neuron-like cells were counted at day 6.
All images were visualized with a Leica SP5 confocal microscope.
SDS-Page and Western blot
To assess the coupling reaction, 1 µM NGF R121W-SNAP was coupled with 1. Membranes were incubated with the following antibodies: anti MAPK (Cell Signaling #4695), anti phospho MAPK (Thr202/Tyr204) (Cell Signaling #9106), anti AKT (Cell Signaling #4691), anti phospho AKT (Ser473) (Cell Signaling #9271), anti-Actin (Cell signaling #4970). Bands were visualized using the ECL detection system (Amersham #RPN2106); band density was calculated using ImageJ and the levels of phosphorylated proteins were normalized to the total counterpart.
Immunofluorescence
Skin from the plantar region of the mice hindpaw was dissected 7 days and 28 days after treatment of SNI mice with IR700, with or without NGF R121W-SNAP , followed by near IR illumination. Skin was fixed with 4% PFA overnight at 4ºC, cryoprotected in 30% sucrose for 6 hours and embedded in Tissue-Tek O.C.T. compound. Twenty-five micrometer thick sections were cut using a cryostat (Leica, CM3050S), permeabilized with 0,3% Triton-X, blocked in 5% goat serum + 0,3% Triton-X and stained for one of the antibodies listed below, prepared in PBS containing 5% goat serum + 0,3% Triton-X. We used K14 were considered for counting [38] .
Knee histology
After intraarticular injection with saline or MIA, knees were dissected out after 7 and 28 days.
The surrounding tissues were trimmed and knees were post-fixed overnight and then placed into a decalcifying solution for 72 hours. Decalcified knees were then washed and embedded in paraffin wax. Eight micrometer thick sections were cut and stained for hematoxylin and eosin and for trichrome staining.
Behavioral testing
All behavior experiments were performed on adult male mice (8-10 week old). Mice were placed on an elevated platform with a mesh floor and habituated for minimum 30 minute, unless otherwise specified.
For the Von Frey test, the plantar side of the hindpaw was stimulated with calibrated von Frey filaments (North Coast medical, #NC12775-99). The 50% paw withdrawal threshold was calculated using the Up-Down method [14] . Post MIA injection, Von Frey testing was confined to the posterior-heel region of the hind paw; post SNI, von Frey testing was confined to the sural nerve innervating region of the paw.
To measure dynamic allodynia, the plantar hind paw was stimulated by stroking using a paint brush (heel-to-toe direction). The responses were scored as previously described [19] as 0 = no response; 1 = brief paw withdrawal; 2 = prolonged paw withdrawal; 3 = paw flicking or licking. Test was performed 5 times, with 1 minute interval between trials.
To measure thermal nociception, mice were placed on a hotplate (Ugo Basile, #35150) preset at 52ºC and video recorded. The latency to response (flicking or licking the hindpaw) was measured. In order to avoid tissue damage, a cut off of 30 seconds was defined.
A hotplate was also used to assess the response to prolonged noxious stimuli. The hotplate was set at 46ºC and 50ºC and different cut offs were set for each temperature: 3 minutes for 46ºC, and 1 minute for 50ºC, as previously described [25] .
Thermal nociception was also evaluated using Hargreaves test, in which a thermal heat stimulus (IR 35) was focused onto the plantar region of the hind paw. To avoid tissue damage, a cut off of 20 seconds was set. The test was repeated 3 times, with 5 minutes interval between trials.
To assess evaporative cold allodynia, the acetone drop test was performed [16] . Briefly, a single drop of cold acetone was applied onto the plantar side of the hindpaw of mice using a syringe without touching the paw of the mice. The responses were scored according to the following scheme: 0 = no response, 1 = paw withdrawal or a single flick, 2 = repeated flicking of the paw and 3 = licking of the paw. The test was repeated five times with 1 minute interval between trials.
For the pin-prick test, the plantar side of the hindpaw was gently touched using an insect pin attached to a 1 g von Frey filament, without penetrating the skin and the yes/no responses were noted for 10 trials, with 1 minute interval between the trials.
For the clip tail test, an alligator clip covered with a rubber casing to reduce the potential tissue damage, was placed on the tail of the mouse, near the base of the tail; then, each mouse was placed on a plexiglass chamber and video recorded. A response was scored when the mice showed a response to the clip by biting, vocalization, grasping of tail or jumping. A cut off of 90 seconds was set and data are plotted as the time to respond (latency) for each mouse.
Complete Freund's Adjuvant model
Complete Freund's Adjuvant (CFA, 20 µl, 2% in 1:1 saline) (Sigma-Aldrich, F5881) was injected into the hindpaw of mice. Behavioral tests were performed at 24h and 48h post CFA injection to assess inflammation, followed by photoablation experiments.
Spared Nerve Injury model
Peripheral nerve injury was induced by spared nerve injury (SNI) [46] . Briefly, mice were anesthetized using 2.5% isoflurane. The sciatic nerve near the thigh region was exposed and the peroneal and tibial branches were ligated and cut, leaving the sural nerve intact.
Behavioral tests were performed starting from 1 week after injury, followed by photoablation experiments.
Osteoarthritis model
As previously described [45] , 10 µl monosodium iodoacetate (MIA, 1mg) (Sigma-Aldrich, I2512) was injected intra-articular, through the intrapatellar ligament, into the knee. Sterile saline was injected in the control mice. Behavioral testing was performed 1 week after the injection.
In-vivo photoablation
The hindpaw, the knee or the tail of the mice were treated for 3 consecutive days with NGF R121W -SNAP (5 µM) coupled to BG-IR700 (15 µM) (20 μl and 10 μl for paw and knee injections, respectively, and 20 μl for microemulsion application). Depending on the experiment, the coupling reaction was delivered by injection, or topically using a microemulsion, as described previously [44] . Twenty minutes after delivery, near infrared light at 690nm was applied to the treated skin for 1 minute, at 120-150 J/cm 2 (PSU-III-FDA diode laser, CNI Laser, China). Behavioral tests were performed starting from 1 day after the last photoablation.
Statistical analysis
All statistical data are presented as standard error of the mean (SEM) along with the number of samples analyzed (n). Student's t-test and/or analysis of variance ANOVA followed by the appropriate post hoc test were used. Statistical significance was assumed at p<0.05. Sample sizes were determined from the power of the statistical test performed. No animals were excluded and all experiments were performed blinded with order of testing randomized.
Discussion
Here we describe an approach based on ligand-targeted, light-activated delivery of a phototoxic agent to ablate nociceptors in the skin and reduce pain behavior in mice. To achieve selective nociceptor ablation in vivo, we engineered the "painless" HSAN V NGF R121W mutant ligand to specifically deliver a photoactivatable photosensitizer locally to TrkA expressing nociceptors. Upon illumination with NIR light we show that there is a highly effective reversal in pain behavior in mouse models of inflammatory, neuropathic and osteoarthritic pain.
The ligand-mediated photoablation technology we describe here has been previously validated in mice using engineered TrkB and IL31-receptor ligands to control mechanical pain hypersensitivity and inflammatory itch [18; 44] . Based on extensive evidence supporting a role for TrkA signaling in pain [27; 31; 34-36; 39; 56; 62], we selected NGF as a delivery agent to target cutaneous nociceptors in vivo. Following local illumination of the skin, we observed retraction of fibers innervating the epidermis, corresponding to a long lasting but reversible reduction in nociceptive behavior. When the pain behavior returned 3 weeks after photoablation, we also observed a concomitant re-growth of the cutaneous sensory fibers, suggesting that we were targeting nociceptors, the major transducers of pain. Importantly, no damage to other cellular types was detected under the conditions used, despite the fact that TrkA receptors are expressed on keratinocytes and other cells in the skin. [7; 36; 55] This is in agreement with our previous study using interleukin-31 (IL-31) as a ligand to target pruriceptors in the skin. Like NGF receptors, IL-31 receptors are highly expressed in keratinocytes, however we found that IL-31-guided photoablation induced keratinocyte cell death only at very high concentrations, and at much higher light intensities than those used here [44] . This would suggest that neurons are more sensitive to IR700 induced photoablation than other cells in the skin. Several recent studies have described naturally occurring mutations in the NGF gene in patients affected by a rare form of congenital insensitivity to pain, HSAN V. The variants pro-NGF R221W (corresponding to the mature NGF R100W ) and NGF R121W have been characterized at the protein level [10; 54; 57] , and it has been demonstrated that both retain the binding to their receptors TrkA and p75, while downstream signaling (auto phosphorylation of TrkA and phosphorylation of MAPK) is impaired, preventing the nociceptive activity typically exerted by NGF. The identification of these "painless" NGF forms opens up the possibility that these mutated ligands may be exploited as drug delivery agents that bind to nociceptors but do not activate them. We explored this possibility here by fusing a SNAP-tag to NGF R121W , and using it to target the small molecule photosensitizer IR700 to nociceptors. Further development of this approach may also allow for the conjugation of other biologically active small molecules to NGF R121W to deliver them into nociceptors in vivo and directly interfere with neuronal activity.
Previous work has shown that selective antagonism of endogenous NGF is highly effective in animal models of many acute and chronic pain states [23; 39; 51] . Among several agents developed to counteract NGF-mediated sensitization, particular attention has focused on monoclonal antibodies such as tanezumab and fasinumab, which have proven effective in the management of osteoarthritic pain [5; 8] . Although these anti-NGF antibodies showed greater efficacy in chronic pain compared to the nonsteroidal anti-inflammatory drugs (NSAIDs), serious adverse effects, including osteonecrosis, neurogenic arthropathy, and morphologic changes in the sympathetic nervous system were reported [4] , leading the US Food and Drug Administration (FDA) to place a hold from 2010 to 2015 on clinical studies involving this class of drugs. The reported adverse effects were similar across anti-NGF monoclonal antibodies, suggesting that they are "class-specific effects" [3] . While new evidence is generated in ongoing phase III clinical trials involving tanezumab and fasinumab in OA, the current evaluation of risk/benefit ratio of anti-NGF therapies remains challenging [5] .
Similar safety concerns may also be pertinent to NGF-mediated photoablation. However, there are a number of important differences in the photoablation approach compared to monoclonal-anti-NGF-based strategies for treating pain. Firstly, photoablation targets cells rather than one specific molecular mediator of pain, enabling the treatment to bypass the enormous molecular complexity that underlies pain, and to circumvent molecular redundancy, a major issue in developing new analgesic drugs. Secondly, the photoablation is local and can be applied on demand. Thus dosage, light intensity, and frequency of application may constitute useful checkpoints for patient-personalized modulation. Compared to approaches based on monoclonal antibodies which are administered systemically, this may reduce offtarget effects on systems other than nociception. Thirdly, our data indicate that a single treatment regime of photoablation is sufficient to obtain analgesia that lasts for several weeks, rather than hours or days, potentially reducing toxicity. Indeed, it may also be possible to increase the effect duration further by performing photoablation in the nerve innervating the injured area, or even to selectively ablate nociceptors permanently in the DRG. Future work, will explore these possibilities and also establish the safety and efficacy of repeated cycles of photoablation.
We found that photoablation using NGF R121W-SNAP was most effective at reducing responses to punctate nociceptive mechanical stimuli. Thus we observed substantially increased von Frey thresholds under basal, inflammatory, osteoarthritic and neuropathic states, and decreased sensitivity to painful clip and pinprick. Of note, behavioral responses to dynamic mechanical stimuli were not altered by photoablation. In previous work we have demonstrated that these dynamic stimuli evoke nociceptive reflexes through TrkB positive mechanoreceptors after nerve injury, and that photoablation using BDNF SNAP is an effective means of reducing these responses [18] . As well as demonstrating that NGF R121W-SNAP and BDNF SNAP mediated photoablation is selective, these data highlight the complexity of sensory processing under different conditions, and indicate that solely targeting nociceptors may not be an optimal strategy in certain pain states.
Given the prominent role of NGF in thermal hyperalgesia, we expected to see a reduction in thermal nociceptive withdrawal latencies in photoablation-treated mice. For example, using a 52ºC stimulus we observed similar latencies between ablated and non-ablated mice in acute tests. Similarly, photoablation failed to revert the reduction in latencies induced in a mouse model of inflammatory pain. This apparent discrepancy could be explained by the fact that residual heat-sensitive cutaneous sensory fibers, not expressing TrkA are preserved by the photoablation and could mediate thermal nociceptive reflexes. Indeed, in a recent study, it has been shown that acute noxious heat sensing in mice depends on a triad of transient receptor potential ion channels: TRPM3, TRPV1, and TRPA1 [60] , and importantly, none of these channels are expressed exclusively in TrkA positive neurons [61] , [58] [26] . Further work using ligands to target other populations of nociceptors for photoablation may uncover the role of these neurons in mediating thermal nociceptive withdrawal reflexes.
While we saw no difference in withdrawal reflexes to heat, we did observe a significant reduction in nocifensive behavior upon prolonged thermal stimulation at 46ºC and 50ºC. It has recently been demonstrated that these two behaviors are driven by distinct inputs from the periphery and the spinal cord to the thalamus [25] . Indeed, in the periphery, it was shown that non-peptidergic MRGPRD positive neurons underlie reflexive responses that limit injury, while TRPV1 positive nociceptors play a role in behavioral responses to prolonged stimuli and the coping response to pain [25] . It is thus tempting to speculate that NGF R121W-SNAP mediated photoablation selectively targets those neurons that input the "suffering" quality of pain, while sparing the first-line defensive neurons. Such qualities would be optimal for analgesic therapy, as the protective aspect of the peripheral nervous system to noxious heat is preserved, while the perceived pain of the burn is reduced. (d-f) Hek293T cells transiently transfected with TrkA and p75 were incubated with NGF SNAP (0.1, 0.5 and 1 μM, panel d, e and f respectively) conjugated with BG-IR700, and then exposed to NIR illumination for 2 min. 24 h post in vitro photoablation, cells where stained with propidium iodide (PI). 1 μM BG-IR700-conjugated NGF SNAP (panel g) was applied onto mock transfected cells, and cells exposed to 690 nm light for 2 min as a negative control. The tests were performed at the indicated day relative to the SNI procedure, and after a 3-d course of injections with NGF R121W-SNAP + IR700 with (n=6, open circles) and without (n=6, closed circles) NIR illumination (red arrow indicates the first day of ablation). Baseline before SNI is set as d= -1. Score=0 no response; score=1 paw withdrawal; score=2 prolonged paw withdrawal; score=3 paw flicking/licking; score=4 prolonged paw licking. *p = 0.005 (twoway ANOVA followed by Bonferroni post hoc test). Figure 5 
Figure legends
